Polyrizon completes contracting for five U.S. NASARIX allergy study sites
AI Summary- Polyrizon completed contracts with its fourth and fifth U.S. clinical sites for NASARIX.
- 120 randomized patients will receive NASARIX or isotonic saline in a 1:1 ratio.
- Enrollment preparations will align with seasonal allergy periods and monitored pollen and weather conditions.